| | Statistical Considerations for FDA COVID-19 Guidance In response to the FDA guidance on COVID-19, we’re committed to highlighting specific, actionable considerations that directly address the agency’s key recommendations. Get our tips for ensuring the operational integrity and scientific robustness of your clinical trial. Premier Research. Built for BiotechSM |
Today's Rundown Experts weigh in on vaccine prospects as dozens of COVID-19 projects race ahead As COVID-19 isolates patients, telehealth becomes lifeline for behavioral health Lilly ad campaign in U.S. newspapers offers diabetes med help for patients affected by COVID-19 shutdowns Vizient warns medicines needed for ventilator patients are running low Biopharma roundup: Amgen, Genfit say they're not expecting 'significant' trial delays, though others might Healthcare roundup: Florida Blue waives cost-sharing; Alignment Healthcare launches crisis meal delivery Amgen sees no 'significant delays' from pandemic to novel KRAS cancer drug Good news for teaching hospitals: U.S. resumes visa processing for physicians Doctors report heartbreaking separation at the end of life as elderly face quarantines Chinese APIs flowing but India ban hinders U.S. approval of hydroxychloroquine COVID-19 not expected to 'significantly delay' Genfit's phase 3 NASH readout Featured Story | | | Tuesday, March 31, 2020 Vaccine researchers are fervently working behind the scenes to hustle a COVID-19 shot to market. Dozens of projects are in the works. FiercePharma convened a panel of experts to assess progress—and outline the challenges that remain. |
|
|---|
|
Top Stories Monday, March 30, 2020 As more Americans are urged to stay at home amid the COVID-19 crisis, it’s not just physical health that’s going largely digital—it's behavioral health, too. Tuesday, March 31, 2020 Eli Lilly wants diabetes patients who use its drugs to know that help is available, and to get the word out, it bought full-page ads in more than a dozen newspapers in the U.S. The simple print ads, which ran Monday, spoke directly to people who recently lost jobs or health insurance and told them to contact the Lilly Diabetes Solution Center for help. Tuesday, March 31, 2020 Healthcare performance company Vizient identified looming potential shortages among 13 drugs found in three drug classes crucial to the use of ventilators, it said in a report released Tuesday. Tuesday, March 31, 2020 Amgen and Genfit said they don't expect significant delays to their lung cancer and NASH drugs, but Akero might not be so lucky. It's about halfway through collecting biopsies for its own NASH therapy, and it isn’t clear at the moment how much COVID-19 will interfere. Tuesday, March 31, 2020 FierceHealthcare's ongoing coverage of how the coronavirus is impacting the healthcare industry. Tuesday, March 31, 2020 Amgen has become the latest biopharma to try to figure out the hit it may take to its pipeline timings amid the COVID-19 pandemic. Tuesday, March 31, 2020 With the increasing need for more physicians to treat coronavirus patients, the U.S. State Department says it will resume processing visas needed by international doctors to enter the country and work here. Tuesday, March 31, 2020 For Simone B. Benatti, M.D. it was a painful conversation with the wife of an elderly man dying in her hospital. The Italian doctor said one of the most wrenching impacts of the coronavirus pandemic is the separation of patients from their families at the end of their lives—one that now hangs over U.S. physicians. Tuesday, March 31, 2020 The production of Chinese active pharmaceutical ingredients (APIs) slipped by 10% to 20% during the early days of the COVID-19 outbreak in China but is quickly recovering. The bottleneck in the global supply chain for APIs is now shipping, particularly ocean freight. Tuesday, March 31, 2020 Genfit has told investors that it does not expect the COVID-19 pandemic to “significantly delay” the unblinding of its phase 3 nonalcoholic steatohepatitis data. The database was locked at the end of February but will only be unblinded after the FDA has provided feedback. |
